The effect of maxacalcitol on cardiovascular disesase in hemodialysis patients
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000002784
- Lead Sponsor
- Department of Medicine and Clinical Science, Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Not provided
Exclusion Criteria
Post history of intravenous vitamin D therapy Post history of cicalcet HCl treatment Post history of peritoneal dialysis or kidney transplantion Pregnant woman Post history of severe cardiovascular disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eft ventricular mass index
- Secondary Outcome Measures
Name Time Method Intimal plus medial complex thickness Coronary artery calcification score Pulse wave velocity Dual energy X-ray absorptiometry Bone metabolism marker Inflamatory marker Oxidative stress marker Parathyroid gland volume Correlation between bone and artery Correlation between vitamin D level and vascular calcification
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link maxacalcitol to cardiovascular risk reduction in hemodialysis patients?
How does maxacalcitol compare to standard vitamin D analogs in managing secondary hyperparathyroidism and cardiovascular outcomes in CKD?
Which biomarkers correlate with maxacalcitol efficacy in hemodialysis patients with calcific uremic arteriolopathy?
What adverse events are associated with maxacalcitol in end-stage renal disease patients and how are they managed?
Are there synergistic effects of combining maxacalcitol with phosphate binders for cardiovascular protection in hemodialysis?